← ANALYST RATINGS · TIPRANKS
ProQR (PRQR): analyst forecast and price target
Analyst consensus
Strong Buy4 Buy0 Hold0 Sell
Ratings of 4 analysts in the last 3 months12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $8.25, the highest $9.00, the lowest $8.00. The average is +529.8% from the last price of $1.31.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $1.50 → $1.00−33.3% | Sell | −23.7% | Downgrade | 17.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $1.50 → $1.00−33.3% | Sell | −23.7% | Downgrade | 17.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 → $1.00−33.3% | Sell | −23.7% | Downgrade | 17.10.26on TipRanks 07:05 | — | |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $12.00 → $8.00−33.3% | Buy | +510.7% | Reiterated | 01.10.26on TipRanks 06:55 | −2.0%next day −0.4% · 5 days −5.0% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $8.00 | Buy | +510.7% | Reiterated | 30.09.26on TipRanks Oct 1 05:09 | +0.8%next day −2.0% · 5 days −3.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $1.50 | Hold | +14.5% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| Steven Seedhouse★★★★★★★★★★#1374 · hits 43% · avg +10.3% | Cantor Fitzgerald | $8.00 | Buy | +510.7% | Reiterated | 14.08.26on TipRanks 08:55 | +4.0%next day +1.0% · 5 days +23.2% | ↗ |
| Kostas Biliouris★★★★★★★★★★#9060 · hits 41% · avg −0.1% | Oppenheimer | $9.00 | Buy | +587.0% | Reiterated | 14.08.26on TipRanks 08:15 | +4.0%next day +1.0% · 5 days +23.2% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $14.00 → $10.00−28.6% | Buy | +663.4% | Reiterated | 26.06.26on TipRanks Jun 29 02:25 | −1.5%next day +18.0% · 5 days +9.4% | ↗ |
| Catherine Novack★★★★★★★★★★#905 · hits 41% · avg +25.1% | JonesTrading | $11.00 → $10.00−9.1% | Buy | +663.4% | Reiterated | 26.06.26on TipRanks Jun 29 02:25 | −1.5%next day +18.0% · 5 days +9.4% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $4.00 → $3.00−25.0% | Buy | +129.0% | Reiterated | 25.06.26on TipRanks 21:00 | −1.5%next day +18.0% · 5 days +9.4% | ↗ |
| Jonathan Wolleben★★★★★★★★★★#249 · hits 53% · avg +23.6% | Citizens JMP | $8.00 | Buy | +510.7% | Reiterated | 12.03.26on TipRanks Mar 27 18:00 | −3.5%next day +6.4% · 5 days −6.6% | |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $5.00 | Buy | +281.7% | Reiterated | 17.12.25on TipRanks Dec 18 06:50 | −4.6%next day −2.6% · 5 days −1.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering ProQR
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $8.25 at a price of $1.66 (+397.0%); now: $8.25 at $1.31 (+529.8%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 7 | 9 | 7 | 7 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.11 (from $-0.17 to $-0.08). Last quarter: $-0.09.
Sales
Next quarter’s sales estimate — $4M (from $0M to $6M). Last quarter: $10M.
Best top-analyst consensus in the sector · Healthcare
About ProQR
- CEO: Daniel Anton de Boer
- Employees: 166
- Zernikedreef 9, Leiden, ZH, 2333 Ck, NL
- www.proqr.com
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Data from the stock’s TipRanks forecast page, read 93 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗